The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy
Abstract
Background: Targeting glioblastoma (GBM) energy metabolism through multiple metabolic pathways has emerged as an effective therapeutic approach. Dual inhibition of phospholipid and mitochondrial metabolism with cytoplasmic phospholipase A2 (cPLA2) knockdown and metformin treatment could be a potential strategy. However, the strategic prerequisite is to explore a carrier capable of co-delivering the therapeutic combination to cross the blood-brain barrier (BBB) and preferentially accumulate at the GBM site. Methods: Blood exosomes (Exos) were selected as the combination delivery carriers. The cellular uptake of Exos and the therapeutic effects of the combination strategy were evaluated in primary GBM cells. In vivo GBM-targeted delivery efficiency and anti-GBM efficacy were tested in a patient-derived xenograft (PDX) model. Results: Here, we showed that the Exos-mediated cPLA2 siRNA/metformin combined strategy could regulate GBM energy metabolism for personalized treatment. Genomic analysis and experiments showed that polymerase 1 and transcript release factor (PTRF, a biomarker of GBM) positively regulated the uptake of Exos by GBM cells, confirming the feasibility of the delivery strategy. Further, Exos could co-load cPLA2 siRNA (sicPLA2) and metformin and co-deliver them across the BBB and into GBM tissue. The mitochondrial energy metabolism of GBM was impaired with this combination treatment (Exos-Met/sicPLA2). In the PDX GBM model, systemic administration of Exos-Met/sicPLA2 reduced tumor growth and prolonged survival. Conclusions: Our findings demonstrated that Exos-based combined delivery of sicPLA2 and metformin selectively targeted the GBM energy metabolism to achieve antitumor effects, showing its potential as a personalized therapy for GBM patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By isolating exosomes from a patient’s own cells, researchers can further reduce the risk of immune rejection, making exosome-based therapies an attractive option for personalized cancer treatment [292].”
From Emerging role of exosomes in cancer therapy: progress and challenges (2025) · cites this paper as [292]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
The current state and future directions of RNAi-based therapeutics
Setten, R. L., Rossi, J. J., & Han, S.-P. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0017-4 · Cited by 1,443
Dopamine-loaded blood exosomes targeted to brain for better treatment of Parkinson’s disease
Qu, M., Lin, Q., Huang, L., Fu, Y., Wang, L., He, S., Fu, Y., Yang, S., Zhang, Z., Zhang, L., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.035 · Cited by 543
Self-citationMa, F., Yang, L., Sun, Z., Chen, J., Rui, X., Glass, Z., & Xu, Q. (2020) · Science Advances · doi:10.1126/sciadv.abb4429 · Cited by 218
Research works printed but not linked: 24
- Ostrom, 2019, CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2012-2016, Neuro Oncol., 21, v1, 10.1093/neuonc/noz150 · DOI
- Tan, 2020, Management of glioblastoma: state of the art and future directions, CA Cancer J Clin., 70, 299, 10.3322/caac.21613 · DOI
- Liberti, 2016, The Warburg effect: how does it benefit cancer cells?, Trends Biochem Sci., 41, 211, 10.1016/j.tibs.2015.12.001 · DOI · Paper page
- Huang, 2021, Targeting phospholipid metabolism for glioblastoma therapy, Neuro Oncol., 23, 343, 10.1093/neuonc/noaa309 · DOI
- Agnihotri, 2016, Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions, Neuro Onco.l, 18, 160, 10.1093/neuonc/nov125 · DOI
- Slatter, 2016, Mapping the human platelet lipidome reveals cytosolic phospholipase A2 as a regulator of mitochondrial bioenergetics during activation, Cell Metab., 23, 930, 10.1016/j.cmet.2016.04.001 · DOI
- Carracedo, 2013, Cancer metabolism: fatty acid oxidation in the limelight, Nat Rev Cancer., 13, 227, 10.1038/nrc3483 · DOI
- Yi, 2021, PTRF/cavin-1 remodels phospholipid metabolism to promote tumor proliferation and suppress immune responses in glioblastoma by stabilizing cPLA2, Neuro Oncol., 23, 387, 10.1093/neuonc/noaa255 · DOI
- Vasan, 2020, Mitochondrial metabolism as a target for cancer therapy, Cell Metab., 32, 341, 10.1016/j.cmet.2020.06.019 · DOI
- Weinberg, 2015, Targeting mitochondria metabolism for cancer therapy, Nat Chem Biol., 11, 9, 10.1038/nchembio.1712 · DOI
- Pollak, 2014, Overcoming drug development bottlenecks with repurposing: repurposing biguanides to target energy metabolism for cancer treatment, Nat Med., 20, 591, 10.1038/nm.3596 · DOI
- Banks, 2016, From blood-brain barrier to blood-brain interface: new opportunities for CNS drug delivery, Nat Rev Drug Discov., 15, 275, 10.1038/nrd.2015.21 · DOI · Paper page
- Carvalho, 2021, Recent advances in co-delivery nanosystems for synergistic action in cancer treatment, J Mater Chem B., 9, 1208, 10.1039/D0TB02168G · DOI
- Tsou, 2017, Drug delivery to the brain across the blood-brain barrier using nanomaterials, Small., 13, 10.1002/smll.201701921 · DOI
- Wang, 2021, Challenges in the development and establishment of exosome-based drug delivery systems, J Control Release., 329, 894, 10.1016/j.jconrel.2020.10.020 · DOI
- Zhan, 2020, Engineering blood exosomes for tumor-targeting efficient gene/chemo combination therapy, Theranostics., 10, 7889, 10.7150/thno.45028 · DOI · Paper page
- Usman, 2018, Efficient RNA drug delivery using red blood cell extracellular vesicles, Nat Commun., 9, 2359, 10.1038/s41467-018-04791-8 · DOI · Paper page
- Yang, 2019, Blood TfR+ exosomes separated by a pH-responsive method deliver chemotherapeutics for tumor therapy, Theranostics., 9, 7680, 10.7150/thno.37220 · DOI
- Cha, 2020, Advances in drug delivery technology for the treatment of glioblastoma multiforme, J Control Release., 328, 350, 10.1016/j.jconrel.2020.09.002 · DOI
- Mathieu, 2019, Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication, Nat Cell Biol., 21, 9, 10.1038/s41556-018-0250-9 · DOI
- Spector, 1985, Membrane lipid composition and cellular function, J Lipid Res., 26, 1015, 10.1016/S0022-2275(20)34276-0 · DOI
- Mehryab, 2020, Exosomes as a next-generation drug delivery system: an update on drug loading approaches, characterization, and clinical application challenges, Acta Biomater., 113, 42, 10.1016/j.actbio.2020.06.036 · DOI · Paper page
- Johnsen, 2019, Targeting the transferrin receptor for brain drug delivery, Prog Neurobiol., 181, 101665, 10.1016/j.pneurobio.2019.101665 · DOI
- Huo, 2020, Versatile hollow COF nanospheres via manipulating transferrin corona for precise glioma-targeted drug delivery, Biomaterials., 260, 120305, 10.1016/j.biomaterials.2020.120305 · DOI
Cited by
Sorted by citations
Emerging role of exosomes in cancer therapy: progress and challenges
Li, J., Wang, J., & Chen, Z. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02215-4 · Cited by 297
Metadata
- Authors
- Zhan, Q., Yi, K., Cui, X., Li, X., Yang, S., Wang, Q., Fang, C., Tan, Y., Li, L., Xu, C., Yuan, X., & Kang, C.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-03-21
- Volume
- 24
- Issue
- 11
- Pages
- 1871-1883
- ISSN
- 1522-8517
- 1523-5866
- Cited by
- 103
- References
- 4
- Language
- en
- Funders
- National Natural Science Foundation of China (81772667, 51773151)
- Tianjin Key R&D Program (20YFZCSY00360)
- Tianjin Science and Technology Program (20YFZCSY00360)
- Hebei Natural Science Foundation Precision Medicine Joint Project (H2020201206)
- National Key Research and Development Program of China (2018YFA0209700)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
